Table of Contents

Blood thinners are essential medications that help prevent uncontrolled blood clotting. Blood clots can lead to serious health risks such as strokes, heart attacks, and pulmonary embolisms. In the United States, over eight million people rely on these medications to manage their risk of developing harmful blood clots, making them a critical component of many patients’ treatment plans.

A diverse array of blood thinner medications are available, including well-known options like Eliquis (apixaban), Warfarin, and Xarelto (rivaroxaban). Some drugs have been around for years and have long established efficacy while there are newer options that offer lesser side effects. Each has its mechanism of action, dosing requirements, and potential side effects.

In this article, we will provide a comprehensive blood thinner medications list and explore their costs, benefits, potential side effects, and more.

Key Takeaways

    • There are two types of blood thinner medications: anticoagulants, which interfere with the clotting process, and antiplatelet agents, which prevent platelets from sticking together.
    • Bleeding is the most common side effect across all types of blood thinners. Gastrointestinal issues, bruising, and in some cases, severe reactions such as thrombocytopenia can also occur.
    • Blood thinners are available in different dosage forms, including tablets (like Eliquis and Warfarin), capsules (such as Pradaxa), and injectable syringes (like Fragmin and Lovenox).
    • The costs of blood thinner medications vary significantly, starting at $36.99 for Warfarin compared to $199 for Xarelto.
    • Some blood thinner medications, particularly Warfarin, require regular blood tests to monitor effectiveness and appropriate dosage levels. In contrast, newer anticoagulants like Eliquis and Xarelto generally do not need routine blood monitoring.

What are the different types of blood thinners?

Anticoagulants 

Anticoagulants prevent blood clots by interfering with the body’s natural clotting process. They target specific proteins involved in coagulation, lowering the risk of serious complications such as heart attacks and strokes. Often prescribed for conditions like atrial fibrillation and deep vein thrombosis, these medications may require regular blood tests to monitor their effectiveness.

Below are the different types of anticoagulants:

    • Vitamin K Antagonists
    • Direct Factor Xa Inhibitors
    • Direct Thrombin Inhibitors
    • Unfractionated Heparin
    • Low Molecular Weight Heparins
    • Fondaparinux

Antiplatelet Agents

Antiplatelet medicines prevent platelets from sticking together to form clots. This is especially essential in preventing arterial blockages, which can lead to a heart attack or stroke. These drugs, which aids in keeping the blood flowing normally, are administered to individuals with heart problems.

What are the most common blood thinners?

Here is the blood thinner medication list with their cost, dosage, side effects, and other information:

1. Eliquis

Eliquis is considered to have a lower risk of serious bleeding compared to some other anticoagulants, making it a safer choice for those concerned with bleeding complications. Studies show that the chance of major bleeding is 3% or less. Non-major bleeding risks are generally between 2% and 4%. Less common side effects, such as nausea, bruising, and minor gum or nose bleeding, occur infrequently (1% to 4%).

Price: Starts at $157 (for 60 tabs of 2.5 mg)

Active ingredients: Apixaban

Drug class: Anticoagulant (Factor Xa inhibitor)

Dosage form: 2.5 mg and 5 mg tablets

Dosage frequency: Twice daily

Approved indications: 

    • Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
    • Prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip or knee replacement surgery.
    • Treatment of DVT and PE and reducing the risk of recurrence after initial therapy.

Common side effects: Bleeding

Pros:

  • Lower risk of heavy bleeding
  • No routine blood monitoring required
  • Reduced stroke risk
  • Oral dosing
  • Lower bleeding risk compared to warfarin
  • Reversal agent availability (Andexxa)

Cons:

  • Twice-daily dosing
  • Higher cost
  • Not recommended for people with prosthetic heart valves
  • Generic alternative unavailable until 2026

2. Fragmin

Research indicates that Fragmin (dalteparin) is highly effective for cancer patients with acute VTE. Using it for an extended period lowers the risk of recurrent blood clots without increasing the likelihood of major bleeding. Compared to standard anticoagulants, Fragmin offers additional advantages, including easy administration during invasive procedures and chemotherapy-induced low platelet counts.

Price: Starts at $84.95 (for 10 prefilled syringes of 0.2 ml)

Active ingredients: Dalteparin

Drug class: Anticoagulant (Heparin)

Dosage form: Single dose prefilled syringe

Dosage frequency: Once or twice daily injection, depending on the condition.

Approved indications: 

    • Ischemic complications of unstable angina and non-Q-wave myocardial infarction in adults
    • DVT prevention in abdominal surgery, hip replacement, or patients with restricted mobility during acute illness in adults
    • Reduce recurrence of symptomatic VTE for adult patients with cancer and pediatric patients (from birth, ?35 weeks gestational age)

Common side effects: Bleeding (including hemorrhage), thrombocytopenia (low number of platelets), hematoma and pain at the injection site, and transient elevation of transaminase (liver enzymes).

Pros:

  • Has generic alternatives
  • Approved in reducing clotting risks for cancer patients
  • No routine blood monitoring required

Cons:

  • Twice-daily dosing
  • Administered by injections
  • More expensive compared to other anticoagulants
  • More side effects compared to other anticoagulants
  • No specific reversal agent; partial reversal may be achieved with protamine sulfate

3. Lovenox

Lovenox (enoxaparin) at a 40 mg daily dose has significantly reduced the risk of VTE in patients with acute medical conditions. In a large study with 1,102 participants, patients receiving 40 mg of Lovenox had a VTE incidence of 5.5%, compared to 14.9% in the placebo group. This protective effect was sustained over three months. There was no significant difference in adverse effects between groups, indicating that Lovenox is both practical and safe for VTE prevention in these patients.

Price: Starts at $84.95 (for 10 prefilled syringes of 0.3 ml)

Active ingredients: Enoxaparin sodium

Drug class: Anticoagulant (Low molecular weight heparin)

Dosage form: Single dose prefilled syringe

Dosage frequency: Once or twice daily injection, depending on the condition.

Approved indications: 

    • DVT prevention in abdominal surgery, hip replacement, knee replacement, or patients with limited mobility due to acute illness.
    • Acute DVT treatment with or without pulmonary embolism.
    • Prevention of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI).
    • Treatment of acute ST-segment elevation myocardial infarction (STEMI), whether managed medically or with percutaneous coronary intervention.

Common side effects: Bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase (liver enzymes), diarrhea, nausea, bruising, fever, edema, dyspnea, confusion, and injection site pain.

Pros:

  • Has generic alternatives
  • Safe to use during pregnancy and breastfeeding
  • Lower risk of heavy bleeding compared to some anticoagulants
  • No routine blood monitoring required

Pros:

  • Has generic alternatives
  • Safe to use during pregnancy and breastfeeding
  • Lower risk of heavy bleeding compared to some anticoagulants
  • No routine blood monitoring required

4. Plavix

In a follow-up study over 5.8 years, Plavix (clopidogrel) proved more effective than aspirin in reducing primary and secondary thrombotic events, significantly decreasing major adverse events (12.8% in Plavix vs. 16.9% in aspirin). Plavix also showed a lower risk of bleeding complications (4.5% vs. 6.1%). The mortality rate was similar between both groups and the benefits of Plavix remained consistent over time. This suggests Plavix is highly effective in decreasing heart complications in patients with drug-eluting stents.

75 mg Plavix tablets

Price: Starts at $69.99 (for 28 tabs of 7.5 mg)

Active ingredients: Clopidogrel

Drug class: Antiplatelet (P2Y12 platelet inhibitor)

Dosage form: 75 mg, 300 mg tablets

Dosage frequency: Once daily

Approved indications: 

    • Acute coronary syndrome (ACS):
      • Non-ST-segment elevation ACS (like unstable angina or non-ST-elevation myocardial infarction).
      • Reduces the risk of cardiovascular death, heart attack (MI), stroke, or worsening chest pain.
    • ST-segment elevation myocardial infarction (STEMI):
      • Lowers the risk of death from any cause and decreases chances of death, repeat heart attack, or stroke.
    • Reduces the risk of new stroke, new heart attack, or death from blood vessel-related issues

Common side effects: Bleeding

Pros:

  • Once daily dosing
  • Has generic alternatives
  • No routine blood monitoring required
  • Moderate risk of bleeding compared to other anticoagulants
  • Rapid onset of action (effects seen within 2 to 4 hours)

Cons:

  • Proton pump inhibitors can reduce its efficacy
  • Contraindicated in people with history of thrombotic thrombocytopenic purpura (TTP) and severe liver impairment
  • No specific reversal agent for Plavix but platelet transfusions may be used

5. Pradaxa

When it comes to safety, Pradaxa has an advantage and disadvantage. A 2021 study suggests that Pradaxa (dabigatran) has a favorable safety profile, with no notable increase in major bleeding, intracranial hemorrhage, fatal adverse reactions, or all-cause mortality compared to controls. However, Pradaxa is linked to a higher risk of gastrointestinal bleeding.

Price: Starts at $120.00 (for 30 capsules of 75 mg)

Active ingredients: Dabigatran

Drug class: Anticoagulant (Direct thrombin inhibitor)

Dosage form: 75 mg, 110 mg and 150 mg capsules

Dosage frequency: Twice daily

Approved indications: 

    • Stroke and systemic embolism prevention in adults with non-valvular atrial fibrillation.
    • Treatment of DVT and PE in adults after 5-10 days of parenteral anticoagulant.
    • Reduction of DVT and PE recurrence risk in previously treated adults.
    • DVT and PE prophylaxis post-hip replacement in adults.
    • VTE treatment in pediatric patients (8-18 years) after 5 days of parenteral anticoagulant.
    • Reduction of VTE recurrence risk in previously treated pediatric patients (8-18 years).

Common side effects: Bleeding and gastrointestinal side effects

Pros:

  • Approved in patients aged eight years and older for reduction of VTE recurrence risk
  • Has generic alternatives
  • No routine blood monitoring required
  • Anticoagulant effects can be reversed with idarucizumab (Praxbind)

Cons:

  • Requires dosing twice daily
  • May cause a higher risk of gastrointestinal bleeding
  • May interact with certain medications, including P-glycoprotein inhibitors (like dronedarone and certain antifungals)

Helpful Article

Learn more about Pradaxa and how it compares to another anticoagulant, Eliquis, in this comparison guide on Eliquis vs Pradaxa.

6. Prasugrel

Regarding safety and efficacy, clinical trials indicate that Prasugrel is associated with statistically significant improvements compared to Clopidogrel across multiple subgroups. While Prasugrel demonstrated superior efficacy, it also exhibited a significantly higher incidence of combined major and minor bleeding events than Clopidogrel. Despite this increased bleeding risk, the overall benefits of Prasugrel in reducing ischemic events suggest that Prasugrel proves to be effective.

Price: Starts at $77.99 (for 30 tabs of 10 mg)

Active ingredients: Prasugrel

Drug class: Antiplatelet (P2Y platelet inhibitor)

Dosage form: 5 mg and 10 mg tablets

Dosage frequency: Once daily

Approved indications: 

    • For UA or NSTEMI patients managed with PCI or stents
    • For STEMI patients managed with primary or delayed PCI
    • Reduces risk of heart attack, stroke, and cardiovascular death in PCI-treated ACS patients.
    • Used with aspirin to prevent clots in ACS patients post-PCI

Common side effects: bleeding, body pains, dizziness, fatigue, and allergic reactions such as rash and hives.

Pros:

  • Taken once daily with or without meals
  • Rapid onset of action, with effects seen within 30 minutes
  • No routine blood monitoring required

Cons:

  • Contraindicated to patients with prior transient ischemic attack or stroke
  • Higher risk of major bleeding compared to some other antiplatelet agents

7. Warfarin

Warfarin is one of the oldest and most commonly used blood thinner medications, approved by the FDA in 1954. In a study of 425 patients with an average age of 70.6 years, 68% were treated with warfarin. Over two years, warfarin users had a significantly lower rate of thromboembolic events (2.7%) than non-users (8.5%), with a 68% reduction in risk.

Warfarin also reduced the annual ischemic stroke rate by 62%. Although the major bleeding rate was slightly higher in warfarin users (2.6% vs. 1.4%), the difference was insignificant. Overall, warfarin significantly reduced thromboembolic events without increasing major bleeding or mortality rates, confirming its effectiveness in this population.

Price: Starts at $36.99 (for 100 tabs of 1 mg)

Active ingredients: Warfarin

Drug class: Anticoagulant (Vitamin K antagonist)

Dosage form: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, and 10 mg tablets

Dosage frequency: Once daily

Approved indications: 

    • Prevention and treatment of DVT
    • Prevention and treatment of PE
    • Reduce the risk of death and recurrent MI
    • Reduce the risk of thromboembolic events such as stroke or systemic embolization after MI

Common side effects: Bleeding and gastrointestinal side effects

Pros:

  • Taken once daily
  • Widely available and affordable
  • Has been used for decades
  • Can be used in patients with mechanical heart valves and certain atrial fibrillation cases

Cons:

  • Requires blood monitoring
  • Interacts with Vitamin K
  • Efficacy can be affected by drug interactions, such as taking herbal supplements like Ginkgo Biloba or Asian Ginseng
  • Contraindicated in patients with malignant hypertension, hemorrhagic tendencies, and pregnancy

Helpful Article

How does the long-established Warfarin compare to the newer blood thinner, Eliquis? Find out in our detailed guide on Eliquis vs Warfarin.

8. Xarelto

Xarelto is a newer blood thinner approved in 2011 that has shown promising results in clinical trials. A comparison study with Warfarin in patients with atrial fibrillation demonstrated that Xarelto is equally effective with Warfarin for preventing stroke or systemic embolism.

While major bleeding events were similar in both groups, Xarelto was associated with significantly lower rates of intracranial hemorrhage (0.5% vs. 0.7%) and fatal bleeding (0.2% vs. 0.5%). These findings suggest that Xarelto is a safe and effective option for stroke prevention, offering a favorable bleeding profile compared to Warfarin.

Price: Starts at $199 (for 100 tabs of 2.5 mg)

Active ingredients: Rivaroxaban

Drug class: Anticoagulant (Factor Xa inhibitor)

Dosage form: 2.5 mg, 10 mg, 15 mg, and 20 mg tablets

Dosage frequency: Once or twice daily, depending on the condition

Approved indications: 

    • Reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation
    • Treatment of DVT
    • Treatment of PE
    • Reduction in the risk of recurrence of DVT or PE
    • Prevention of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery
    • Prevention of VTE in acutely ill medical patients
    • Reduce the risk of major cardiovascular events in patients with CAD
    • Reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD
    • Treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years
    • For thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure

Common side effects: Bleeding, cough, vomiting, and gastroenteritis.

Pros:

  • Approved for VTE treatment in patients from birth to older
  • Fewer contraindications
  • Fewer drug interactions
  • No routine blood monitoring required

Cons:

  • No generic form available
  • One of the most expensive anticoagulants
  • No specific reversal agent available (though andexanet alfa can reverse some effects)
  • May interact with other medications, including strong CYP3A4 inhibitors and inducers

Final Thoughts

Blood thinner medications are essential in treating serious complications in patients with various cardiovascular and thromboembolic disorders. However, anticoagulants and antiplatelet drugs are not all the same, so careful consideration is needed when selecting the right treatment. It’s important to consider factors like cost, side effects, and whether a specific medication truly fits a condition. Talking with a healthcare provider can help find the option that best suits a patient’s health needs.

Frequently Asked Questions

The “best” blood thinner depends on individual health status, medical history, and the illness being treated. Common options include Eliquis (apixaban), Warfarin, and Xarelto (rivaroxaban), each with unique efficacy, side effect profiles, and monitoring requirements. Patients should consult their healthcare providers to determine the most appropriate medication.
Ibuprofen has a mild blood-thinning effect, but it’s not classified as a blood thinner. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, inflammation, and fever. However, its blood-thinning effect is relatively mild and short-lived compared to prescription anticoagulants like warfarin.
Tylenol (acetaminophen) is not a blood thinner. It relieves pain and reduces fever that does not significantly affect blood clotting or platelet function. Acetaminophen can be a safer option for pain relief for patients on blood thinners. Consult a physician for personalized advice.
Natural blood thinners refer to foods and supplements that may help reduce blood clotting. Common examples include garlic, ginger, turmeric, cinnamon, and omega-3 fatty acids found in fish oil. While these may have mild anticoagulant properties, they should not replace prescribed medications, and patients should always discuss any supplements with their healthcare providers.
Blood thinner medications require prescription. While there are no over-the-counter medications classified explicitly as blood thinners, nonprescription drugs, such as aspirin and certain NSAIDs, have blood thinning effects and may reduce clotting. However, it’s important to use these carefully and consult a doctor, especially for individuals already on prescription blood thinners.
Studies show that blood thinners do not directly lower blood pressure. A patient cannot take blood thinner medications when they have uncontrolled hypertension as it can increase bleeding risk. Hypertensive patients should discuss comprehensive treatment options with their healthcare provider.
Patients on blood thinners, especially Warfarin, should be cautious with foods high in vitamin K, such as leafy greens (e.g., spinach, kale) because they can interfere with the medication’s effectiveness. Alcohol, chamomile, green tea, cranberry and grapefruit juice should be avoided or taken in small amounts. Specific foods and supplements that may interact with a blood thinner medication should be discussed with a healthcare provider.
Stopping blood thinners can significantly increase the risk of developing blood clots, which can lead to severe complications like strokes or pulmonary embolisms. Patients should never discontinue these medications without consulting their healthcare provider.
It is not recommended to drink alcohol while on blood thinners. Alcohol itself acts as a blood thinner and can add to the effects of the drug. It enhances the risk of heavy bleeding, which can be a serious complication. If a person chooses to drink, it is advised to limit consumption to no more than one to two drinks at a time.

Sources

Stop the Clot. (n.d.). Living your best life while taking blood thinners. Retrieved from https://www.stoptheclot.org/living-your-best-life-while-taking-blood-thinners/

MedlinePlus. (n.d.). Blood thinners. Retrieved from https://medlineplus.gov/bloodthinners.html

U.S. Food and Drug Administration. (2012). Plavix (clopidogrel) tablets prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf

Pfizer. (n.d.). Lovenox (enoxaparin sodium) prescribing information. Retrieved from https://labeling.pfizer.com/showlabeling.aspx?id=2293

Sanofi. (n.d.). Lovenox prescribing information. Retrieved from https://products.sanofi.us/lovenox/lovenox.pdf

U.S. Food and Drug Administration. (2010). Lovenox (enoxaparin sodium) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020839s048lbl.pdf

Boehringer Ingelheim. (n.d.). Pradaxa capsules prescribing information. Retrieved from https://content.boehringer-ingelheim.com/DAM/c669f898-0c4e-45a2-ba55-af1e011fdf63/pradaxa%20capsules-us-pi.pdf

U.S. Food and Drug Administration. (2011). Pradaxa (dabigatran etexilate mesylate) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022307s003lbl.pdf

MedlinePlus. (n.d.). Drug information: Prasugrel. Retrieved from https://medlineplus.gov/druginfo/meds/a682277.html

U.S. Food and Drug Administration. (2011). Effient (prasugrel) tablets prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf

Janssen Pharmaceuticals. (n.d.). Xarelto (rivaroxaban) prescribing information. Retrieved from https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf

National Center for Biotechnology Information. (n.d.). National Institutes of Health. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK507910/

American Heart Association. (2022). Practice guidelines for anticoagulation in patients with atrial fibrillation. Retrieved from https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.122.062770

National Center for Biotechnology Information. (2021). PMCID: PMC7901998. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7901998/

National Center for Biotechnology Information. (2009). PMCID: PMC2650665. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC2650665/

National Health Service. (n.d.). Common questions about warfarin. Retrieved from https://www.nhs.uk/medicines/warfarin/common-questions-about-warfarin/

New England Journal of Medicine. (2010). A comparison of rivaroxaban and warfarin in patients with atrial fibrillation. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa1009638

MedlinePlus. (n.d.). Drug information: Dabigatran from https://medlineplus.gov/druginfo/meds/a682159.html

Medical News Today. (2019). Ginger as a natural blood thinner. Retrieved from https://www.medicalnewstoday.com/articles/322384#ginger

Kaiser Permanente. (n.d.). Blood thinners to avoid prior to surgery. Retrieved from https://mydoctor.kaiserpermanente.org/ncal/article/blood-thinners-to-avoid-prior-to-surgery-san-rafael-medical-center-ophthalmology-191550

Cleveland Clinic. (n.d.). Anticoagulants: What you need to know. Retrieved from https://my.clevelandclinic.org/health/treatments/22288-anticoagulants

Mayo Clinic. (2022). Warfarin: What to know about this anticoagulant. Retrieved from https://www.mayoclinic.org/diseases-conditions/thrombophlebitis/expert-answers/warfarin/faq-20058443

Stop the Clot. (n.d.). Managing anticoagulants. Retrieved from https://www.stoptheclot.org/about-clots/managing-anticoagulants/

National Center for Biotechnology Information. (2015). Dalteparin (Fragmin). In Safer Use of Medications (pp. 1-5). https://www.ncbi.nlm.nih.gov/books/NBK279433/

Sweeney, M. M., & Goehring, A. O. (2005). Anticoagulant therapy in the outpatient setting: A review of the evidence. American Family Physician, 71(9), 1802-1814. https://www.aafp.org/pubs/afp/issues/2005/0501/p1802.html